Back to School: How biopharma can reboot drug development. Access exclusive analysis here
GPC Biotech (FSE:GPC; GPCB) said it will restructure and reduce its headcount by 46 (15%) to 270. The move affects GPC's U.S. staff, with cuts in
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury